All In Biotech

Free tool

FAERS Monitor: Striverdi Respimat

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 203108 or its brand name (Striverdi Respimat, Olodaterol Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

369

Serious

183

50% of reports

Hospitalization

95

Death reported

19

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • dyspnoea54
  • cough35
  • off label use32
  • drug ineffective30
  • asthma14
  • chest pain13
  • chronic obstructive pulmonary disease13
  • pneumonia13
  • asthenia12
  • chest discomfort11
  • dizziness10
  • palpitations10
  • wheezing10
  • death9
  • fatigue9

Reports by year received

View as table
YearReports
20111
201420
201556
201653
201747
201822
201929
202025
202129
202222
202322
202415
202515
202613

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,790 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
chronic obstructive pulmonary diseaseSignal1314.28.3147
wheezingSignal109.65.269
coughSignal357.15.2180
asthmaSignal147.14.267
chest discomfortSignal116.13.442
dyspnoeaSignal545.44.2196
palpitationsSignal104.92.627
chest painSignal134.02.327
pneumoniaSignal132.31.38
off label useSignal322.11.518
asthenia121.81.04
drug ineffective301.30.92
dizziness101.10.60
fatigue90.70.31
death90.60.32

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.